October 19, 2021

The eyes and ears of afrikans beyond afrika

A Race for a Cure or a Race for Profits?

Johnson & Johnson on Tuesday said it expected to report eagerly-awaited data on its COVID-19 vaccine early next week, and that it would be able to meet the delivery target for doses to countries with which it had signed supply agreements.
Public health officials are increasingly counting on single-dose options like the one being tested by J&J to simplify and boost inoculations given the complications and slower-than-hoped rollout of authorized vaccines from Pfizer Inc and Moderna Inc, which require second shots weeks after the first.
The company forecast 2021 profit well above Wall Street estimates, and its shares rose 3.4% to $171.55.
The outlook does not include any contribution from the COVID-19 vaccine, Chief Financial Officer Joseph Wolk said.
Read on………..